Phase i study of panobinostat in combination with bevacizumab for recurrent high-grade glioma

Journal of Neuro-Oncology

Volumn 107, Issue 1, 2012, Pages 133-138

  Drappatz, J ^a   Lee, E Q ^a   Hammond, S ^a   Grimm, S A ^b   Norden, A D ^a   Beroukhim, R ^a   Gerard, M ^a   Schiff, D ^c   Chi, A S ^d   Batchelor, T T ^d   Doherty, L M ^a   Ciampa, A S ^a   LaFrankie, D C ^a   Ruland, S ^a   Snodgrass, S M ^e   Raizer, J J ^b   Wen, P Y ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bevacizumab; High grade glioma; Histone deacetylase inhibitor; Panobinostat; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; PANOBINOSTAT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGUS HEMORRHAGE; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; HYPOGLYCEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; MYCOSIS; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VAGINITIS; BRAIN TUMOR; CLINICAL TRIAL; FOLLOW UP; GLIOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; HYDROXAMIC ACIDS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84861696508     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0717-z     Document Type: Article

References (29)

1. CBTRUS (2009) CBTRUS. Statistical report: primary brain tumors in the United States, 2000-2004. http://www.cbtrus.org/reports/2009-NPCR-04-05/CBTRUS- NPCR2004-2005-Report-.pdf. Accessed October 2009
2. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492-507
3. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-4740
4. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of singleagent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5): 740-745
5. Desjardins A, Reardon DA et al (2008) Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 14(21):7068-7073
6. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253-1259
7. Norden AD, Drappatz J, Wen PY (2008) Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7(12):1152-1160
8. Quant EC, Norden AD, Drappatz J et al (2009) Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11(5):550-555
9. Atadja P (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280(2): 233-241
10. Gensert JM, Baranova OV, Weinstein DE, Ratan RR (2007) CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells. Neurobiol Dis 26(3): 671-680
11. Ugur HC, Ramakrishna N, Bello L et al (2007) Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. J Neurooncol 83(3):267-275
12. Yin D, Ong JM, Hu J et al (2007) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 13(3):1045-1052
13. Sharma V, Koul N, Joseph C, Dixit D, Ghosh S, Sen E (2010) HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. J Cell Mol Med 14(8):2151-2161
14. Eyupoglu IY, Hahnen E, Trankle C et al (2006) Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Mol Cancer Ther 5(5):1248-1255
15. Wetzel M, Premkumar DR, Arnold B, Pollack IF (2005) Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis. J Neurosurg 103(6 Suppl):549-556
16. Eyupoglu IY, Hahnen E, Buslei R et al (2005) Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 93(4):992-999
17. Sawa H, Murakami H, Kumagai M et al (2004) Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol 107(6):523-531
18. Galanis E, Jaeckle KA, Maurer MJ et al (2009) Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27(12):2052-2058
19. Deroanne CF, Bonjean K, Servotte S et al (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21(3):427-436
20. Qian DZ, Kato Y, Shabbeer S et al (2006) Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 12(2):634-642
21. Qian DZ, Wang X, Kachhap SK et al (2004) The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64(18):6626-6634
22. Sawa H, Murakami H, Ohshima Y et al (2002) Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells. Brain Tumor Pathol 19(2):77-81
23. Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1):83-95
24. Mandawat A, Fiskus W, Buckley KM et al (2010) Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Blood 116(24):5306-5315
25. Kioi M, Vogel H, Schultz G et al (2010) Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120(3):694-705
26. Rubin JB, Kung AL, Klein RS et al (2003) A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 100(23):13513-13518
27. Lin R, Hu J, Paul S, et al. (2009) Characteristics of thrombocytopenia in patients treated with oral panobinostat (LBH589). Blood (ASH Annual Meeting Abstracts) 114: Abstract 2740
28. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963-1972
29. Novartis (2011) LBH 589 (Panobinostat) Investigator's Brochure 7th edn, Brochure. Basel, Switzerland